More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Executive Summary
Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.
You may also be interested in...
Biocon Breaks Ground In Latin America Through Agreement In Brazil
Having together achieved success with biosimilar trastuzumab in Brazil, Biocon and local player Libbs Farmaceutica have reached an agreement to offer the Indian firm’s generic formulations in the market.
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.
Biocon, Dr Reddy’s Might Be Out Of The Woods On GMP Issue
Two Indian firms – Biocon and Dr Reddy’s – have received crucial establishment inspection reports (EIRs) from the US FDA amid improved compliance levels at their manufacturing sites.